Specifically, retatrutide is intended to activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor a combination that distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist)
These half-steps give each receptor system more time to adapt
GERD, or Gastroesophageal Reflux Disease, is a condition where stomach acid frequently flows back into the tube connecting your mouth and stomach (esophagus)
The perfect candidate is someone who maintains healthy habits but has those frustrating areas where fat persists despite their best efforts. Your skins elasticity plays an important role too
CagriSema combines amylin and GLP-1 signaling through a cagrilintide/semaglutide co-formulation, while retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously through a single tri-agonist molecule
